OLMA Olema Pharmaceuticals, Inc.

CIK 0001750284 50 ready 8-Ks latest October 15, 2026, 5:00 PM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline Risk accumulating: repeated leadership change (2)

Ready 8-Ks 50

Latest filing October 15, 2026, 5:00 PM ET

Top materiality 0.80

Event mix other_material ×22 · earnings ×13 · other ×8

Sentiment 19 pos · 1 neg · 30 neu

Latest earnings ▲ beat 2026-Q1

Executive change recent →

Recent 8-K filings for OLMA

Highest-materiality recent filing

Olema Pharma enters Novartis collaboration for Phase 3 breast cancer trial and raises $250M

December 2, 2024, 6:59 PM ET other material materiality 0.80 positive item 1.01 item 3.02 item 7.01 item 9.01

Collaboration with Novartis provides ribociclib supply for planned Phase 3 OPERA-02 trial of palazestrant in ER+/HER2- frontline advanced/metastatic breast cancer, initiation expected mid-2025.
$250M private placement: 19,928,875 shares at $9.08 and pre-funded warrants for 7,604,163 shares; gross proceeds ~$250M, closing expected Dec 4, 2024.

Read filing →

October 15, 2026, 5:00 PM ET leadership materiality 0.20 neutral item 5.02 ◈ executive_change

Olema director Gorjan Hrustanovic resigns; Prakash Raman named to two board committees

Dr. Gorjan Hrustanovic notified Olema on October 12, 2026 of his resignation from the Board of Directors, effective October 14, 2026.
August 13, 2026, 7:05 AM ET leadership materiality 0.50 neutral item 5.02 item 7.01 item 9.01

Olema Pharmaceuticals appoints Jason O'Byrne as CFO, effective Aug 11, 2026

O'Byrne previously CFO at Vir Biotechnology (2024-2026) and Caribou Biosciences (2021-2024); joins Olema from Vir.
August 10, 2026, 4:05 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Olema Q2 2026 net loss $63.2M, cash $461.1M; OPERA-01 enrollment complete

Net loss $63.2M vs $43.8M in Q2 2025; R&D expenses $57.8M vs $43.9M (GAAP).
June 23, 2026, 4:19 PM ET other materiality 0.10 neutral item 5.07

Olema shareholders elect directors, approve executive compensation, ratify auditor at 2026 annual meeting

Four Class III directors elected: Bohen (67.5M for), Garland (66.2M), Larson (50.4M), Rappaport (67.3M).
May 26, 2026, 7:05 AM ET other material materiality 0.55 positive item 7.01 item 8.01 item 9.01

Olema partners with Bayer for OP-3136 + darolutamide Phase 1b/2 in mCRPC; 36 patients, H2 2026 start

Olema and Bayer will evaluate OP-3136 (KAT6 inhibitor) combined with darolutamide in ~36 mCRPC patients.
May 21, 2026, 5:05 PM ET other material materiality 0.65 positive item 7.01 item 8.01 item 9.01

Olema announces Phase 1 data for OP-3136: tumor shrinkage in 13/19 evaluable, no DLTs

OP-3136 monotherapy well-tolerated up to 45 mg; no DLTs, no discontinuations due to TRAEs.
May 12, 2026, 7:05 AM ET earnings materiality 0.55 negative item 2.02 item 9.01 ◈ Earnings Releases

Olema reports Q1 net loss $53.1M, cash $505.3M; Phase 3 OPERA-01 data due fall 2026

Cash, equivalents, and marketable securities $505.3M as of March 31, 2026.
May 1, 2026, 7:59 PM ET other material materiality 0.40 neutral item 1.01 item 2.03 ◈ Material Agreements

Olema enters 7-year lease for ~38K sq ft corporate HQ in San Francisco

Lease with KR Oyster Point II, LLC for 38,176 sq ft on 4th and 5th floors.
April 29, 2026, 7:59 PM ET leadership materiality 0.50 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change

Olema Pharmaceuticals appoints Dr. Prakash Raman to Board of Directors

Dr. Raman appointed as Class II director effective April 28, 2026; term expires at 2028 annual meeting.
March 16, 2026, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01 ◈ Earnings Releases

Olema reports FY2025 net loss of $162.5M; cash $505.4M; OPERA-01 data fall 2026

Net loss Q4 $46.1M, full year $162.5M; R&D expenses $43.2M and $157.7M respectively.
January 30, 2026, 6:59 PM ET leadership materiality 0.55 neutral item 5.02 item 9.01

Olema CFO/COO Kovacs departs Jan 30; CEO Bohen interim principal financial officer

Shane Kovacs, COO and CFO, leaves Jan 30, 2026; not due to disagreement with company on financial operations.
January 12, 2026, 6:59 PM ET other material materiality 0.50 positive item 2.02 item 7.01 item 9.01

Olema reports preliminary cash >$500M as of Dec 31, 2025

Preliminary unaudited cash, equivalents and marketable securities exceed $500M (subject to year-end close).
November 19, 2025, 6:59 PM ET other material materiality 0.65 neutral item 8.01 item 9.01

Olema Pharmaceuticals announces $190M follow-on offering of 10M shares at $19.00

Offering of 10,000,000 shares of common stock at $19.00 per share for gross proceeds of ~$190M.
November 18, 2025, 6:59 PM ET other materiality 0.20 neutral item 8.01

Olema terminates ATM prospectus; no further sales until new filing

Terminated ATM prospectus effective November 18, 2025.
November 10, 2025, 6:59 PM ET earnings materiality 0.55 neutral item 2.02 item 9.01

Olema Q3 net loss $42.2M; cash $329M; initiates OPERA-02 Phase 3; Pfizer deal

Net loss $42.2M for Q3 2025 vs $34.6M Q3 2024; cash, equivalents and securities $329.0M.
October 20, 2025, 7:59 PM ET other material materiality 0.75 positive item 7.01 item 8.01 item 9.01

Olema reports palazestrant + ribociclib Phase 1b/2 mPFS of 15.5 months in ER+/HER2- MBC

As of July 8, 2025, 72 patients enrolled across 90 mg and 120 mg palazestrant dose cohorts with ribociclib 600 mg.
September 2, 2025, 7:59 PM ET other material materiality 0.65 positive item 7.01 item 8.01 item 9.01

Olema enters clinical trial agreement with Pfizer for palazestrant + atirmociclib phase 1b/2

Phase 1b/2 study to evaluate safety and combinability of palazestrant plus Pfizer’s investigational CDK4 inhibitor atirmociclib in ER+/HER2- metastatic breast cancer.
August 11, 2025, 7:59 PM ET other material materiality 0.70 neutral item 2.02 item 7.01 item 9.01

Olema Q2 net loss $43.8M, selects 90 mg palazestrant dose for Phase 3 trials, cash $361.9M

Q2 net loss $43.8M vs $30.4M YoY; increase driven by $10M Aurigene milestone and higher R&D for late-stage trials.
June 13, 2025, 7:59 PM ET other materiality 0.10 neutral item 5.07

Olema shareholders elect three Class II directors, approve say-on-pay, ratify EY

Cynthia Butitta: 44,675,129 for, 11,733,848 withheld; Cyrus Harmon: 43,838,514 for, 12,570,463 withheld; Graham Walmsley: 44,120,432 for, 12,288,545 withheld.
May 13, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Olema Q1 2025: $392.7M cash, net loss $30.4M; palazestrant combo mPFS 13.8 months

Cash, cash equivalents, and marketable securities of $392.7M at March 31, 2025; net loss $30.4M.
March 18, 2025, 7:59 PM ET earnings materiality 0.50 neutral item 2.02 item 9.01

Olema reports FY2024 net loss $129.5M; cash $434.1M; palazestrant Phase 3 on track

Net loss Q4 $33.6M, FY $129.5M vs. $26.8M and $96.7M in 2023; R&D expense $124.5M FY.
March 5, 2025, 6:59 PM ET other materiality 0.10 neutral item 7.01 item 9.01

Olema Pharmaceuticals posts investor presentation with no material new disclosures

Company made investor presentation available on its website on March 5, 2025.
January 13, 2025, 6:59 PM ET other materiality 0.10 neutral item 7.01 item 9.01

Olema Pharmaceuticals makes investor presentation available; no specific facts disclosed

Company filed Form 8-K with investor presentation dated January 13, 2025.
January 10, 2025, 6:59 PM ET other material materiality 0.55 neutral item 3.02 item 9.01

Olema exchanges ~6.07M shares for pre-funded warrants with Bain, Paradigm, BVF

Entered exchange agreements to swap 6,070,000 common shares for pre-funded warrants at $0.0001 exercise price.
December 10, 2024, 6:59 PM ET other material materiality 0.75 positive item 7.01 item 8.01 item 9.01

Olema gets FDA IND clearance for OP-3136; palazestrant combo shows 73% 6-month PFS

FDA cleared IND for KAT6 inhibitor OP-3136; Phase 1 to start early 2025.
December 2, 2024, 6:59 PM ET other material materiality 0.80 positive item 1.01 item 3.02 item 7.01 item 9.01

Olema Pharma enters Novartis collaboration for Phase 3 breast cancer trial and raises $250M

Collaboration with Novartis provides ribociclib supply for planned Phase 3 OPERA-02 trial of palazestrant in ER+/HER2- frontline advanced/metastatic breast cancer, initiation expected mid-2025.
November 12, 2024, 6:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Olema Pharma Q3 net loss $34.6M; cash $214.8M; OP-3136 IND on track

Q3 2024 net loss $34.6M vs $21.5M in Q3 2023; GAAP R&D $33.2M (up from $19.5M).
September 27, 2024, 7:59 PM ET other material materiality 0.60 neutral item 7.01 item 8.01 item 9.01

Olema targets IND for KAT6 drug OP-3136 in Q4 2024; Phase 1/2 starts 2025

Non-clinical data for OP-3136 (KAT6 inhibitor) to be presented at ENA symposium Oct 23-25, 2024.
August 6, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Olema Q2 net loss $30.4M; cash $239.1M; palazestrant combo shows 85% CBR

Net loss for Q2 2024 was $30.4M vs $20.1M in Q2 2023, driven by increased R&D spending on late-stage trials.
July 2, 2024, 7:59 PM ET debt materiality 0.65 neutral item 1.01 item 2.03

Olema Pharmaceuticals amends loan facility, ups potential borrowing to $100M, extends maturity to 2028

Borrowing capacity increased from $50M to up to $100M with $25M immediately available.
June 14, 2024, 7:59 PM ET other materiality 0.10 neutral item 5.07

Olema annual meeting results: directors elected, compensation approved, auditor ratified

Ian Clark elected with 33,874,399 for; Sandra Horning 40,102,098 for; Gorjan Hrustanovic 44,334,757 for.
May 15, 2024, 7:59 PM ET other material materiality 0.75 positive item 7.01 item 8.01 item 9.01

Olema reports interim Phase 1b/2 data: palazestrant + ribociclib shows 85% CBR in ER+/HER2- mBC

Combination well tolerated in 50 patients; no new safety signals and no clinically meaningful drug-drug interaction.
May 8, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases

Olema reports Q1 net loss of $31.0M; cash $249M; enrollment complete in two palazestrant combo studies

Net loss of $31.0M for Q1 2024 vs $28.3M a year ago; cash & equivalents $249.0M.
March 11, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases ×2

Olema reports FY2023 net loss $96.7M, cash $261.8M; palazestrant Phase 3 underway

Cash, equivalents and marketable securities $261.8M as of Dec 31, 2023; net loss $96.7M for FY2023 vs $104.8M in FY2022.
January 8, 2024, 6:59 PM ET other material materiality 0.55 positive item 7.01 item 8.01 item 9.01

Olema nominates OP-3136, KAT6 inhibitor for breast cancer; IND submission targeted by end of 2024

OP-3136 is an orally bioavailable, potent KAT6A/B-selective inhibitor for ER+ breast cancer.
January 8, 2024, 6:59 PM ET other materiality 0.10 neutral item 7.01 item 9.01

Olema makes investor presentation available for JP Morgan Conference; no financial details disclosed

Presentation furnished as Exhibit 99.1, dated January 8, 2024.
January 5, 2024, 6:59 PM ET other material materiality 0.60 neutral item 1.01 item 8.01 item 9.01 ◈ Material Agreements

Olema Pharmaceuticals enters $150M ATM equity offering with TD Cowen, terminates prior Oppenheimer ATM

Enters ATM agreement with Cowen and Company (TD Cowen) to sell up to $150M of common stock at market prices.
December 6, 2023, 6:59 PM ET other material materiality 0.20 neutral item 7.01 item 9.01

Olema furnishes investor presentation at SABCS; no specific data disclosed

Investor presentation dated December 6, 2023 made available on company website.
December 5, 2023, 6:59 PM ET other material materiality 0.75 positive item 7.01 item 8.01 item 9.01

Olema reports positive Phase 1b/2 combo data for palazestrant; Phase 3 OPERA-01 enrolling

Palazestrant + ribociclib (19 patients) well-tolerated; no dose-limiting toxicities, no drug-drug interaction.
November 7, 2023, 6:59 PM ET earnings materiality 0.60 positive item 2.02 item 9.01 ◈ Earnings Releases

Olema reports Q3 net loss $21.5M, cash $276.9M; OPERA-01 Phase 3 on track

Net loss $21.5M vs $22.7M YoY; cash, equivalents and marketable securities $276.9M.
October 23, 2023, 7:59 PM ET other material materiality 0.80 positive item 7.01 item 8.01 item 9.01

Olema reports Phase 2 palazestrant results: median PFS 4.6 mo in all patients; 7.2 mo in 2nd/3rd-line subset

Palazestrant (OP-1250) median PFS of 4.6 months (CBR 40%) in 86 heavily pretreated metastatic ER+/HER2- breast cancer patients.
October 18, 2023, 7:59 PM ET leadership materiality 0.45 positive item 5.02 item 7.01 item 9.01 ◈ executive_change

Olema appoints Scott Garland to board of directors with extensive launch experience

Scott Garland appointed to Olema's Board as Class III director effective Oct 16, 2023.
October 17, 2023, 7:59 PM ET leadership materiality 0.60 positive item 1.01 item 7.01 item 9.01

Olema appoints Scott Garland to Board; brings commercial expertise for late-stage palazestrant development

Scott Garland appointed to Board as Class III director effective Oct 16, 2023; term through 2026 annual meeting.
October 10, 2023, 7:59 PM ET other material materiality 0.60 positive item 1.01 item 7.01 item 9.01 ◈ Material Agreements

Olema and Novartis expand Phase 1/2 combo study of palazestrant + ribociclib to ~60 patients

Amendment adds ~30 patients to dose expansion, increasing study size to about 60 total.
September 5, 2023, 7:59 PM ET other material materiality 0.75 positive item 1.01 item 2.03 item 3.02 item 9.01 ◈ Material Agreements ×2

Olema raises $130M equity, secures $50M credit facility from SVB

Private placement of 13,211,382 shares at $9.84/share raises ~$130M gross.
August 8, 2023, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases

Olema reports Q2 net loss $20.1M; cash $167.4M; Phase 3 trial on track Q4 2023

Net loss $20.1M for Q2 2023, down from $32.9M in Q2 2022; R&D expenses $18.0M.
June 21, 2023, 7:59 PM ET other materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×3

Olema holds annual meeting; stockholders elect three directors, approve say-on-pay, ratify E&Y auditor

Sean P. Bohen, Yi Larson, and Andrew Rappaport elected as Class III directors through 2026 with votes 23.5M, 18.0M, and 23.7M for respectively.
May 11, 2023, 7:59 PM ET other material materiality 0.70 positive item 8.01 item 9.01

Olema reports Phase 1b/2 data for OP-1250 + palbociclib in ER+/HER2- mBC

Combination of OP-1250 (up to 120 mg) with palbociclib 125 mg was safe and well-tolerated in 29 patients, with no DDI.
May 9, 2023, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

Olema Pharma Q1 net loss $28.3M, cash $186M; Phase 3 trial of OP-1250 planned H2 2023

Cash, cash equivalents and marketable securities of $186.0M as of March 31, 2023, expected to fund operations into 2025.
March 10, 2023, 6:59 PM ET other material materiality 0.60 positive item 7.01

Olema confirms no cash deposits or securities at Silicon Valley Bank

Company holds zero cash or securities at Silicon Valley Bank.

Executive changes

Departed

Gorjan Hrustanovic

Director

OLMA · Olema Pharmaceuticals, Inc.

Effective: 2026-10-14
Filed: October 15, 2026, 5:00 PM ET

On October 12, 2026, Dr. Gorjan Hrustanovic notified Olema Pharmaceuticals, Inc. (the “Company”) of his decision to resign from the Company’s Board of Directors (the “Board”), effective October 14, 2026. Dr. Hrustanovic also resigned from the Compensation Committee of the Board (the “Compensation Committee”) and the Science and Technology Committee of the Board (the “Science and Technology Committee”). Dr. Hrustanovic’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

Appointed

Prakash Raman

Class II director

OLMA · Olema Pharmaceuticals, Inc.

Effective: 2026-04-28
Filed: April 29, 2026, 7:59 PM ET

the Board appointed Dr. Prakash Raman to the Board as a Class II director, effective April 28, 2026

Appointed

Scott Garland

Class III Director

OLMA · Olema Pharmaceuticals, Inc.

Effective: 2023-10-16
Filed: October 18, 2023, 7:59 PM ET

appointed Scott Garland to the Board as a Class III director, effective October 16, 2023

Role change

Peter Kushner

Senior Research Fellow and Co-Founder

OLMA · Olema Pharmaceuticals, Inc.

Effective: 2022-04-01
Filed: March 14, 2022, 7:59 PM ET

On March 10, 2022, Peter Kushner, Ph.D., Chief Scientific Officer (“CSO”) of Olema Pharmaceuticals, Inc. (the “Company”), and the Company agreed that Dr. Kushner would transition from CSO to Senior Research Fellow and Co-Founder, a non-executive role, effective April 1, 2022.

Earnings & guidance

2026-Q1 EPS reported -$0.52 vs consensus -$0.54 ▲ beat (+3.6%) filing →

Materiality & sentiment trend

Max materiality 0.80 · Median 0.60 · Most common event other_material

19 positive 1 negative 30 neutral

source · OLMA on sec.gov